Business
Jaguar Health Reports 2025 Financials
Net revenue increase of 5% in Q4 2025 vs. Q3 2025 Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi®and Canalevia®-CA1 - Jaguar's commercialized ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Net revenue increase of 5% in Q4 2025 vs. Q3 2025","length":49,"tagName":"p"},{"type":"text","content":"Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's commercialized crofelemer drugs - with an additional $2 million due upon completion of post-closing conditions; and has received $3.0 of up to $20 million in milestone payments and other future payments","length":400,"tagName":"p"},{"type":"text","content":"Agreement with Future Pak is fully aligned with Jaguar's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure indications moving forward","length":183,"tagName":"p"},{"type":"text","content":"Jaguar will appeal Nasdaq's March 5, 2026 noncompliance determination related to Nasdaq Listing Rule 5550(a)(2) at a hearing on April 7, 2026; delisting is stayed pending the panel's final decision","length":205,"tagName":"p"},{"type":"text","content":"REMINDER: Friday, April 10, Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q4 2025 financials and company updates; Click here to register","length":153,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / April 7, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated fourth-quarter 2025 financial results.","length":206,"tagName":"p"},{"type":"text","content":"2025 FOURTH QUARTER COMPANY FINANCIAL RESULTS:","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net Revenue: The total net revenue for the Company's prescription products (Mytesi®, Gelclair®, and Canalevia®-CA1), non-prescription products, and license revenue was approximately $3.2 million in the fourth quarter of 2025, representing an increase of 5% over the total net revenue in the third quarter of 2025, which totaled approximately $3.1 million, and a decrease of approximately 8% over the total net revenue in the fourth quarter of 2024, which totaled approximately $3.5 million.","length":494,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":494,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"In 2025, approximately $11.2 million out of the Company&#...